February 10, 2023
Life Sciences
  • The Senate Judiciary Committee approved via voice vote five bipartisan drug pricing bills that could go before the full Senate soon. One of the bills would limit anticompetitive “pay-for-delay” deals that prevent or delay the introduction of affordable follow-on versions of branded pharmaceuticals. Others look to eliminate citizen petition abuses and set a definition for product hopping that can be considered anticompetitive. Judiciary Chair Richard Durbin said he thinks they have “a running start” to have the bills considered on the floor since all of the bills have passed out of the committee before. However, they never advanced and could face resistance in a divided Congress. (Article here; Press release here)